Prodromal Schizophrenia Clinical Trial
Official title:
Neurofeedback Processing Speed Training to Improve Social Functioning in Teenagers and Young Adults at Clinical High Risk for Psychosis
Verified date | February 2024 |
Source | Hartford Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community. This study looks to target a specific cognitive skill called processing speed to see if improving the ability to process information in a timely manner will improve social function in adolescents and young adults at risk for developing schizophrenia. Half will receive neurofeedback cognitive training targeting processing speed while the other half will receive an active control.
Status | Completed |
Enrollment | 81 |
Est. completion date | December 1, 2021 |
Est. primary completion date | December 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 25 Years |
Eligibility | Inclusion Criteria: - Case identification and ascertainment depends on the fulfillment of the Criteria of Prodromal States as evaluated using the Structured Interview for Prodromal Syndromes: (1) attenuated positive symptom state which includes the emergence or worsening over the past year of non-psychotic disturbances in thought content, thought process or perceptual abnormality, (2) brief intermittent positive symptoms, and (3) genetic risk and deterioration. - Processing speed at least 0.5 Standard Deviation below the norm, as indexed by baseline performance on Digit Symbol Coding of 8 or below - Age range 12-25 (this age range also comprises the main period of risk for psychosis) - Written informed consent by patients >18 years old, and written assent by subjects <18 years old, with written informed consent by both parents (unless one is deceased or unavailable). Participants who turn 18 while in the study will be re-consented as adults through written informed consent. Exclusion Criteria: - Current or past diagnosis of psychotic disorder noted at baseline assessment (schizophrenia, schizophreniform, bipolar, schizoaffective, major depression with psychotic features, substance-induced psychosis, psychosis due to a medical condition. - Neurological, neuroendocrine or major medical disorders: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders (clinical interview), including seizure disorder and history of significant traumatic brain injury - Intelligence Quotient < 70: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders - Positive symptoms that occur only in the context of substance abuse or withdrawal (i.e. within one month), so as not to include those at risk for substance-induced psychotic disorder - Lack of fluency in English: subjects must speak English to complete behavioral assessments for which psychometric properties have been established in English, complete cognitive training, and in order to comprehend and comply with protocol requirements. - Substance abuse or dependence (including alcohol and marijuana) in previous six months: for purposes of standardization and interpretation of cognitive data. |
Country | Name | City | State |
---|---|---|---|
United States | Connecting Adolescents with Psychosis (CAP), Child & Adolescents Day Program | Hartford | Connecticut |
United States | Olin Neuropsychiatry Research Center | Hartford | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Hartford Hospital | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change on the Wechsler Intelligence Scale Processing Speed Index | Change on a paper and pencil test of processing speed | Baseline, 1 month, 2 month, 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03149107 -
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
|
Phase 3 | |
Recruiting |
NCT05131035 -
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
|
N/A | |
Completed |
NCT01269710 -
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
|
N/A | |
Enrolling by invitation |
NCT05567848 -
Accelerated TMS in Psychosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT03751865 -
Early Detection and Intervention for Women At-risk of Psychosis
|
N/A | |
Recruiting |
NCT05052853 -
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
|
Phase 2 | |
Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
Completed |
NCT01597141 -
Psychosis: Early Detection, Intervention and Prevention
|
N/A | |
Completed |
NCT00169988 -
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
|
N/A | |
Completed |
NCT06190483 -
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
|
N/A | |
Completed |
NCT01619319 -
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
|
N/A | |
Recruiting |
NCT05167396 -
REtinal and VIsual Cortical Response in Early PSYchosis
|
N/A | |
Terminated |
NCT00169949 -
Aripiprazole Treatment of the Prodrome
|
N/A | |
Recruiting |
NCT04338152 -
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
|
N/A | |
Recruiting |
NCT05142735 -
Effects of NAC on Symptoms of CHR Patients
|
N/A | |
Enrolling by invitation |
NCT05532683 -
Feasibility Trial of a Lifestyle Intervention for CHR-P
|
N/A | |
Enrolling by invitation |
NCT03970005 -
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
|